Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Clinical trial NCT07537400 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07537400
- Sponsor
- Shaare Zedek Medical Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-01
- Primary completion
- 2028-06-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.